🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
276

Quick answer

Takeda has 276 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Midazolam

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  2. Midazolam

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  3. Midazolam

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. Midazolam

    Takeda

    Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. Mobocertinib

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  6. Mobocertinib

    Takeda

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  7. Mobocertinib

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. Mobocertinib

    Takeda

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  9. Niraparib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  10. No Intervention

    Takeda

    Rheumatoid Arthritis

    phase 1 other completed

    1 trial

  11. NoV GI.1/GII.4 Bivalent VLP Vaccine

    Takeda

    Gastroenteritis

    phase 1 mab completed

    1 trial

  12. Ontamalimab

    Takeda

    Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  13. Pembrolizumab

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  14. Pevonedistat

    Takeda

    Advanced Solid Tumors, Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  15. Pevonedistat

    Takeda

    Myelofibroses

    phase 1 small molecule terminated

    1 trial

  16. Pevonedistat

    Takeda

    Refractory Acute Lymphoblastic Leukemia

    phase 1 small molecule completed

    1 trial

  17. Pevonedistat

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  18. Pevonedistat

    Takeda

    Advanced Solid Neoplasm

    phase 1 small molecule completed

    2 trials

  19. Pevonedistat 25 mg/m^2

    Takeda

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  20. Pioglitazone

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  21. Placebo

    Takeda

    Virus, Zika

    phase 1 small molecule completed

    1 trial

  22. Ponatinib

    Takeda

    Chronic Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  23. PvP001 100 mg

    Takeda

    Digestive System Disease

    phase 1 small molecule completed

    1 trial

  24. Radiolabeled Prucalopride Succinate

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  25. Radiolabeled SPD557

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  26. Radiolabeled SPD602 (FBS0701, SSP-004184)

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  27. Ramelteon 8 mg

    Takeda

    Insomnia

    phase 1 small molecule completed

    1 trial

  28. Recombinant ADAMTS13

    Takeda

    Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

    phase 1 small molecule completed

    1 trial

  29. Recombinant human C1 esterase inhibitor

    Takeda

    Hereditary Angioedema (HAE)

    phase 1 small molecule completed

    1 trial

  30. Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)

    Takeda

    Von Willebrand Disease

    phase 1 mab completed

    1 trial

  31. Roflumilast

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  32. SHP465 12.5mg

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 1 small molecule completed

    1 trial

  33. SHP639 (n=60)

    Takeda

    Primary Open-angle Glaucoma (POAG)

    phase 1 small molecule completed

    1 trial

  34. SHP643

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  35. SHP681

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  36. SPD422

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  37. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  38. SPD503

    Takeda

    Healthy

    phase 1 small molecule completed

    2 trials

  39. SPD544

    Takeda

    ADHD

    phase 1 small molecule completed

    1 trial

  40. SSP-002358

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  41. SSP-004184

    Takeda

    Impaired Renal Function

    phase 1 small molecule completed

    1 trial

  42. SSP-004184

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  43. SSP-004184AQ

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  44. SSP-004184SS

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  45. SYR-472

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  46. Sapanisertib

    Takeda

    Non-hematologic Malignancy

    phase 1 small molecule completed

    1 trial

  47. Scopolamine

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  48. Simvastatin

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

276 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.